CoChat

Diabetes, antidiabetic medications and risk of depression – A population-based cohort and nested case-control study

Open access
Wium-Andersen, Ida Kim, Osler, Merete, Jørgensen, Martin Balslev, Rungby, Jørgen, Wium-Andersen, Marie Kim · 2022 · Psychoneuroendocrinology
Cited by 86

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Diabetes type 2 is associated with depression, but the impact of antidiabetic drugs is not clear. The objective was to analyze the association between diabetes type 2, antidiabetic drugs, and depression. METHODS: This register-based study included 116.699 patients with diabetes type 2 diagnosed from 2000 to 2012 and an age, gender, and municipality matched reference group of 116.008 individuals without diabetes. All participants were followed for a diagnosis of depression or prescription of antidepressant medication. Based on this, a case-control study was nested within the cohort, using risk set sampling. Antidiabetic medication was categorized into insulin, metformin, sulfonylureas and glinides combined, glitazones, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide 1 (GLP1) analogs, sodium-glucose transport protein 2 (SGLT2) inhibitors and acarbose. The association between diabetes and depression was analyzed using Cox proportional hazards regression, whereas conditional logistic regression was used to analyze the association between use of antidiabetic drugs and depression. RESULTS: Patients with diabetes had higher risk of depression compared to individuals without diabetes (hazard ratio 1.14 (95% confidence interval 1.14-1.15)). Low doses of metformin, DPP4 inhibitors, GLP1 analogs, and SGLT2 inhibitors were associated with lower risk of depression in patients with diabetes compared to non-users, with the lowest risk for sodium-glucose transport protein 2 inhibitor users (odds ratio 0.55 (0.44-0.70)). Use of insulin, sulfonylurea and high doses of metformin were associated with higher risk of depression. CONCLUSION: Patients with diabetes had increased risk of depression. However, users of specific antidiabetic drugs had lower risk of depression compared to non-users.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.psyneuen.2022.105715

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 35

  1. Akimoto, 2019, Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: a retrospective cohort study, Pharmacol. Res. Perspect., 7
  2. Ali, 2006, The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis: review article, Diabet. Med, 23, 1165, 10.1111/j.1464-5491.2006.01943.x · DOI · Paper page
  3. Ankarfeldt, 2017, Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study, Clin. Epidemiol., Volume 9, 19, 10.2147/CLEP.S124054 · DOI
  4. Bai, 2018, The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis, BMJ Open, 8, 10.1136/bmjopen-2017-020062 · DOI
  5. Berge, 2015, Depression in persons with diabetes by age and antidiabetic treatment: a cross-sectional analysis with data from the hordaland health study, PLOS ONE, 10, 10.1371/journal.pone.0127161 · DOI
  6. Bock, 2009, Validity of the diagnosis of a single depressive episode in a case register, Clin. Pract. Epidemiol. Ment. Health, 5, 4, 10.1186/1745-0179-5-4 · DOI · Paper page
  7. Brietzke, 2018, Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments, Neurosci. Biobehav. Rev., 94, 11, 10.1016/j.neubiorev.2018.07.020 · DOI · Paper page
  8. Carstensen, 2011, The national diabetes register, Scand. J. Public Health, 39, 58, 10.1177/1403494811404278 · DOI · Paper page
  9. Chireh, 2019, Diabetes increases the risk of depression: a systematic review, meta-analysis and estimates of population attributable fractions based on prospective studies, Prev. Med. Rep., 14
  10. Etminan, 2004, Pharmacoepidemiology II: the nested case-control study–a novel approach in pharmacoepidemiologic research, Pharmacotherapy, 24, 1105, 10.1592/phco.24.13.1105.38083 · DOI
  11. Gamble, 2018, Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink, BMJ Open, 8, 10.1136/bmjopen-2018-023830 · DOI · Paper page
  12. Gupta, 2015, Diabetes-associated depression: the serotonergic system as a novel multifunctional target, Indian J. Pharm., 47, 4, 10.4103/0253-7613.150305 · DOI
  13. Harding, 2019, Depression prevalence in Type 2 diabetes is not related to diabetes–depression symptom overlap but is related to symptom dimensions within patient self‐report measures: a meta‐analysis, Diabet. Med., 36, 1600, 10.1111/dme.14139 · DOI · Paper page
  14. Helweg-Larsen, 2011, The Danish register of causes of death, Scand. J. Public Health, 39, 26, 10.1177/1403494811399958 · DOI · Paper page
  15. Jensen, 2020, Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases, Int. J. Mol. Sci., 21, 8767, 10.3390/ijms21228767 · DOI · Paper page
  16. Kessing, 2020, Antidiabetes agents and incident depression: a nationwide population-based study, Diabetes Care, 43, 3050, 10.2337/dc20-1561 · DOI · Paper page
  17. Kim, 2016, Hyperglycemia reduces efficiency of brain networks in subjects with type 2 diabetes, PLOS ONE, 11
  18. Lahelma, 2004, Pathways between socioeconomic determinants of health, J. Epidemiol. Community Health, 58, 327, 10.1136/jech.2003.011148 · DOI · Paper page
  19. Lloyd, 2012, Epidemiology of depression in diabetes: international and cross-cultural issues, J. Affect. Disord., 142, S22, 10.1016/S0165-0327(12)70005-8 · DOI
  20. Lopresti, 2013, A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise, J. Affect. Disord., 148, 12, 10.1016/j.jad.2013.01.014 · DOI · Paper page
  21. Moulton, 2018, Repositioning of diabetes treatments for depressive symptoms: a systematic review and meta-analysis of clinical trials, Psychoneuroendocrinology, 94, 91, 10.1016/j.psyneuen.2018.05.010 · DOI · Paper page
  22. Mudgal, 2019, Possible involvement of metformin in downregulation of neuroinflammation and associated behavioural changes in mice, Inflammopharmacology, 27, 941, 10.1007/s10787-019-00638-w · DOI
  23. Nilsson, 2018, The effects of incretin hormones on cerebral glucose metabolism in health and disease, Neuropharmacology, 136, 243, 10.1016/j.neuropharm.2017.12.031 · DOI
  24. Pedersen, 2011, The Danish civil registration system, Scand. J. Public Health, 39, 22, 10.1177/1403494810387965 · DOI · Paper page
  25. Qiu, 2017, Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives, Diabetes Metab. Res. Rev., 33, 10.1002/dmrr.2886 · DOI · Paper page
  26. Roos, 2007, Insulin resistance and self-rated symptoms of depression in Swedish women with risk factors for diabetes: the Women’s Health in the Lund Area study, Metabolism, 56, 825, 10.1016/j.metabol.2007.01.013 · DOI
  27. Rosso, 2015, Glucose metabolism alterations in patients with bipolar disorder, J. Affect. Disord., 184, 293, 10.1016/j.jad.2015.06.006 · DOI
  28. Sa-nguanmoo, 2017, SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats, Toxicol. Appl. Pharmacol., 333, 43, 10.1016/j.taap.2017.08.005 · DOI · Paper page
  29. Schmidt, 2015, The Danish National Patient Registry: a review of content, data quality, and research potential, Clin. Epidemiol., 449, 10.2147/CLEP.S91125 · DOI · Paper page
  30. Wahlqvist, 2012, Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study, BMC Med, 10
  31. Wallach Kildemoes, 2011, The Danish national prescription registry, Scand. J. Public Health, 39, 38, 10.1177/1403494810394717 · DOI · Paper page
  32. Watson, 2018, Insulin resistance, an unmasked culprit in depressive disorders: promises for interventions, Neuropharmacology, 136, 327, 10.1016/j.neuropharm.2017.11.038 · DOI · Paper page
  33. Wium-Andersen, 2021, Hemoglobin A1c-levels and subsequent risk of depression in individuals with and without diabetes, J. Diabetes Complicat., 35, 10.1016/j.jdiacomp.2021.107946 · DOI
  34. Yaribeygi, 2020, Neuromodulatory effects of anti-diabetes medications: a mechanistic review, Pharmacol. Res., 152, 10.1016/j.phrs.2019.104611 · DOI · Paper page
  35. Zheng, 2016, Increased dipeptidyl peptidase-4 activity is associated with high prevalence of depression in middle-aged and older adults: a cross-sectional study, J. Clin. Psychiatry, 77, e1248, 10.4088/JCP.15m10154 · doi:10.4088/jcp.15m10154

Cited by

See all 86

Metadata

Authors
Wium-Andersen, I. K., Osler, M., Jørgensen, M. B., Rungby, J., & Wium-Andersen, M. K.
Venue
Psychoneuroendocrinology
Publisher
Elsevier BV
Published
2022-06
Volume
140
Pages
105715
ISSN
0306-4530 (ISSN-L)
OpenAlex
W4220819731
Cited by
86
References
15
FWCI
9.94
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Jascha Fonden
  • Lundbeckfonden
  • Danish Medical Association Research Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetes, antidiabetic medications and risk of depression – A population-based cohort and nested case-control study. https://app.cochat.ai/papers/10.1016/j.psyneuen.2022.105715
The paper
Wium-Andersen, I. K., Osler, M., Jørgensen, M. B., Rungby, J., & Wium-Andersen, M. K. (2022). Diabetes, antidiabetic medications and risk of depression – A population-based cohort and nested case-control study. Psychoneuroendocrinology. https://doi.org/10.1016/j.psyneuen.2022.105715

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.